Search Results

Iran Says Its Atomic Energy Organization's Medical Products Serve Over 1.5 Million Patients Annually

Mohammad Eslami, head of the Atomic Energy Organization of Iran, recently stated that more than 1.5 million patients in Iran use diagnostic and therapeutic products developed by the organization each year, and related medical products have also been exported to multiple countries. Eslami made these remarks at a ceremony held by Iran's nuclear industry to celebrate Physicians' Day. He said that promoting the application of advanced treatment methods is one of the key directions of Iran's scientific and technological development. The progress made by Iranian researchers in cold plasma technology has opened up a "brand-new and promising path" for medical applications. He stated that plasma technology has not only achieved notable results in the research field but has also played a role in healthcare settings.

2026-08-24

Hengyang New Radiopharmaceutical Isotope and Drug Industrialization Project Officially Launched

On August 22, the groundbreaking ceremony for the Hengyang New Radiopharmaceutical Isotope and Drug Industrialization Project was held in Hengyang, Hunan Province. Officials from Hengyang City and Zhuhui District, representatives from relevant colleges of the University of South China, investment institutions, and relevant personnel from New Radiopharmaceutical Medical attended the event. Cai Jiming, Chairman and President of New Radiopharmaceutical Medical, stated at the ceremony that the project's landing in Hengyang represents an important strategic layout for the company's nuclear medicine business. From contract signing to construction commencement, the project has received support from local governments, partners, and relevant organizations. The company will leverage this project as an opportunity to continue advancing the transformation of innovative achievements in the fields of medical isotopes and radiopharmaceuticals. Wang Jing, Deputy Mayor of Hengyang City, stated that Hengyang...

2026-08-22

CNNC Particle and Beijing Institute of Medical Device Testing Carry Out Joint Learning and Co-building Activity

On August 20, CNNC Particle and the Beijing Institute of Medical Device Testing carried out a joint learning and co-building activity. Representatives from both sides engaged in in-depth discussions on topics such as Party building leading business development, joint development of technical standards, and enhancement of inspection and testing capabilities. Wu Wei, Secretary of the Party Branch and Director of CNNC Particle, Wu Kechun, Deputy Secretary of the Party Committee of the Institute, and more than twenty Party member representatives from both sides participated in the event. At the beginning of the event, the CNNC Particle delegation visited the Institute's laboratories to gain first-hand understanding of its technical capabilities and research progress in inspection and testing. The Institute's advanced experimental platforms and technologies left a deep impression on the visitors. During the discussion session, Wu Kechun and Wu Wei delivered speeches respectively. Both sides...

2026-08-22

South Korea's Asan Medical Center Develops AI-Based Radiopharmaceutical Therapy Platform with U.S. Institutions

The research team at Asan Medical Center in Seoul announced on the 21st that it has recently been selected for the "2026 Korea-U.S. Innovative Outcomes R&D New Support Project" organized by the Ministry of Health and Welfare, and will collaborate with U.S. research institutions to develop an artificial intelligence-based radiopharmaceutical therapy platform aimed at exploring new treatment strategies for solid tumors that respond poorly to conventional therapies. The team is composed of professors including Myung Seung-jae from the Department of Gastroenterology, Oh Seung-jun from the Department of Nuclear Medicine, Ryu Chang-hoon from the Department of Oncology, Jung Byung-kwan from the Department of Pathology, and Son Byung-ho from the Department of Breast Surgery at Asan Medical Center. The project will combine Asan Medical Center's large-scale clinical and pathological data, Emory University's AI-based digital pathology analysis technology, and Case Western Reserve University and University Hospitals Cleveland Medical Center's pathological and clinical research capabilities.

2026-08-22

Research reactors provide critical support for global medical, scientific, and industrial innovation

The International Atomic Energy Agency recently reported that research reactors continue to play a vital role in medical, scientific, industrial innovation, and nuclear workforce development, serving as key infrastructure for many countries to build their nuclear science and technology capabilities. Currently, 228 research reactors are in operation across 54 countries worldwide, with another 23 under construction or in the planning stage. Unlike nuclear power reactors used for electricity generation, research reactors primarily produce neutrons for applications in medicine, industry, agriculture, geological sciences, forensics, and other fields. With capabilities such as neutron irradiation, neutron imaging, elemental analysis, and radioisotope production, research reactors have become important platforms for advancing peaceful nuclear technology applications. In the medical field, research...

2026-08-23

Construction of Radiotherapy and Radiosurgery Center Completed at Bulgaria's St. Ivan Rilski University Hospital

All construction and repair work for the new Radiotherapy and Radiosurgery Center at Bulgaria's St. Ivan Rilski University Hospital has been fully completed. According to the hospital, a latest-generation medical linear accelerator has been installed in the center, capable of sub-millimeter patient positioning accuracy. The equipment was delivered by the Ministry of Health under the National Recovery and Resilience Plan, as part of the investment project for the modernization of the national system for diagnosis and treatment of oncological diseases, funded by the European Commission's Recovery and Resilience Facility. The device is a TrueBeam-EDGE linear accelerator manufactured by Varian Medical Systems, equipped with BrainLab's ExactTrac Dynamic system, valued at 5.1 million...

2026-08-21

Five New Oncology Diagnostic and Treatment Devices at Bulgaria's ISUL Hospital Expected to Launch This Autumn

Queen Joanna - ISUL University Hospital in Bulgaria expects to begin operating five new devices for imaging diagnosis and treatment of oncological diseases starting early this autumn. The hospital stated that patients will be able to use these high-tech devices after the relevant licensing and approval procedures are completed. Source: Queen Joanna University Hospital - ISULThe newly added equipment is deployed in the imaging diagnostics department and the radiation oncology department. Among them, the radiation therapy department will be equipped with a TrueBeam v4.1 medical linear accelerator, primarily used for radiotherapy and radiosurgery. This device can deliver high-energy radiation to tumor tissue with greater precision, supporting high-precision dose planning to achieve the required therapeutic effect while minimizing radiation exposure to healthy tissues and organs surrounding the tumor.

2026-08-21

University of South China team extracts high-purity medical alpha nuclide Lead-212 from rare earth slag

On August 20, it was learned from the University of South China that the team led by Professor Wei Yuezhou successfully separated and obtained high-purity alpha nuclide Lead-212 and its precursor nuclide Thorium-228 directly from rare earth slag, achieving the extraction of 158 microcuries of Lead-212/Bismuth-212 from kilogram-level rare earth slag in a single batch. The achievement recently passed the scientific and technological achievement appraisal meeting for the "Technology Development for Extracting Medical Alpha Nuclide Lead-212 and Thorium-228 from Radium Slag from Monazite Processing" organized by the China Isotope and Radiation Association. Experts unanimously agreed that the overall technology has reached internationally advanced level, with single-pass recovery rate reaching internationally leading level, which is expected to promote China's independent supply of medical alpha nuclides and ensure the security of the nuclear medical industry chain, with broad application prospects...

2026-08-21

Full-Life Technologies Completes Construction of Belgian Radiopharmaceutical Production Facility and Initiates Accelerator Commissioning

Full-Life Technologies (hereinafter referred to as "Full-Life"), a privately held, fully integrated, clinical-stage international radiopharmaceutical therapy company, announced on August 20 that its radiopharmaceutical production facility in Gembloux, Belgium, has completed construction and received authorization to commence accelerator commissioning and enter the initial ramp-up phase. (Full-Life Technologies Belgium Radiopharmaceutical Production Facility) This milestone marks a significant step forward in Full-Life's vertically integrated radioisotope production capabilities moving toward formal operational status. With the completion of facility construction, the company has entered the next phase of operational preparation, including accelerator installation, phased commissioning, and validation of critical safety and operational systems.

2026-08-20

Second Radiotherapy Linear Accelerator Commissioned at Buchholz Hospital in Germany

The second medical linear accelerator for cancer radiotherapy at Buchholz Hospital in the North Heath region of Germany has been commissioned. The device was activated by the hospital's radiotherapy department under the direction of Chief Physician Dr. Günter Bohlen, marking a further enhancement of local oncological radiotherapy capabilities. The management of Buchholz Hospital and Winsen Hospital, Dr. Franziska von Brunnig (third from right) and Dr. Martin Meyer (first from right), together with Chief Physician Dr. Günter Bohlen (second from right) and the radiotherapy team, posed for a photo at the official commissioning ceremony of the second linear accelerator at Buchholz Hospital. Photo: Buchholz-Winsen Hospital. According to available information, Buchholz Hospital...

2026-08-20

Canada Approves Bruce Power Hot Cell Facility Operations, Strengthening Lutetium-177 Medical Isotope Supply Chain

Bruce Power has recently received approval from the Canadian Nuclear Safety Commission to operate its on-site hot cell facility for target carrier removal (TCR) work, a critical step in the production process of the medical isotope lutetium-177 (Lu-177). Lu-177 is used in the treatment of prostate cancer and is increasingly applied in targeted therapies for precision medicine. Under the approval, Bruce Power can perform the relevant processing steps on site, further streamlining the isotope production process, reducing transportation requirements, while helping to enhance operational safety, lower emissions, and strengthen Ontario's capabilities in the global medical isotope supply chain. The hot cell facility was completed earlier this year...

2026-08-20

Norway's Thor Medical AlphaOne High-Purity Alpha Radioisotope Facility to Be Officially Inaugurated

Thor Medical ASA announced on August 19 that its AlphaOne production facility at the Herøya industrial park in Norway will be officially inaugurated on September 9, 2026, with Norwegian Prime Minister Jonas Gahr Støre attending the ceremony. According to reports, AlphaOne is Thor Medical's first industrial-scale production facility for high-purity α radioisotopes and the first of its kind globally. The facility is already in operation, primarily producing isotope products for next-generation targeted cancer therapies, supplying high-purity α emitters to the radiopharmaceutical industry. Thor Medical CEO Jasper Kurth stated that AlphaOn...

2026-08-19

Kazakhstan's Institute of Nuclear Physics Plans to Expand Medical Radioisotope Production and Export

The Institute of Nuclear Physics (INP) of Kazakhstan is progressively expanding the applications of radioisotopes and radiation technologies, with related products already used in cancer diagnosis and treatment, industrial production, and scientific research. Institute Director Sayabek Sakhiyev stated that radioisotope and radiopharmaceutical production is one of the institute's key applied activities, covering the full chain from scientific research and research reactor operation to radiochemical technology development and medical applications. Currently, INP produces three main categories of radiopharmaceuticals: sodium iodide I-131 for thyroid disease treatment, Mo-99/Tc-99m related products for radionuclide diagnostics, and...

2026-08-18

Libya Plans to Restore Tajoura Research Reactor for Medical Isotope Production

The Libyan Atomic Energy Establishment recently proposed a plan to restore and restart the Tajoura nuclear research reactor for the production of medical radioisotopes. The establishment stated that this initiative aims to support the diagnosis and treatment of diseases and tumors, while reducing dependence on imports of relevant isotopes. Radioisotopes are essential materials in nuclear medicine, serving as tracers in medical imaging to help track organ function and detect certain diseases and tumors; some isotopes are also used in radiotherapy targeting specific tissues. According to the Libyan Atomic Energy Establishment, the Tajoura reactor has a rated thermal power of 10 megawatts and holds potential for producing various medical isotopes, including...

2026-08-18

NRC to Hold Online Public Meeting on Proposed Medical Use Licensing Rule

The U.S. Nuclear Regulatory Commission recently announced it will hold an online public meeting from 1:00 p.m. to 2:30 p.m. Eastern Time on August 20 to introduce the proposed rule aimed at reducing barriers to medical use licensing. The proposed rule was published in the Federal Register on July 27. During the meeting, NRC staff will outline the key provisions of the rule and related implementation activities, and answer questions from the public. The meeting is open to the public and will focus on regulatory processes related to medical use licensing, with the goal of explaining and discussing the proposed rule and subsequent implementation arrangements...

2026-08-16